lidocaine has been researched along with Hepatocellular Carcinoma in 22 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetics and clinical activity of epirubicin were investigated in 16 patients with hepatocellular carcinoma (HCC) who received epirubicin at 75 mg/m2; the drug was given intravenously to 7 patients and via the hepatic artery to 9 patients (7 of whom also underwent embolisation)." | 9.07 | Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity. ( Dobbs, NA; Johnson, PJ; Metivier, EM; Rizzi, P; Twelves, CJ; Warwick, JD; Williams, R, 1994) |
| "Lidocaine plays an anticancer role in hepatocellular carcinoma." | 8.02 | Lidocaine Inhibits Hepatocellular Carcinoma Development by Modulating circ_ITCH/miR-421/CPEB3 Axis. ( Chen, F; Li, J; Liu, G; Ma, N; Mao, N; Zhao, L, 2021) |
| "Lidocaine displays antitumor activity by inducing apoptosis and suppressing tumor growth in human hepatocellular carcinoma (HepG2) cells in vitro." | 7.88 | Effects of Lidocaine-Mediated CPEB3 Upregulation in Human Hepatocellular Carcinoma Cell Proliferation In Vitro. ( Chen, B; Li, W; Liu, H; Shen, X; Wang, Y, 2018) |
| " However, the function and underlying mechanisms of lidocaine in hepatocellular carcinoma both in vitro and in vivo have been poorly studied." | 7.85 | Lidocaine Induces Apoptosis and Suppresses Tumor Growth in Human Hepatocellular Carcinoma Cells In Vitro and in a Xenograft Model In Vivo. ( Chen, DT; Chen, YH; Li, Q; Pan, JH; Xing, W; Xue, RF; Yan, Y; Yuan, YF; Zeng, WA, 2017) |
| "To assess the efficacy of intraarterial lidocaine on peri- and post-procedural pain and on length of hospital stay in hepatocellular carcinoma (HCC) patients undergoing chemoembolization." | 7.72 | Chemoembolization for hepatocellular carcinoma: effect of intraarterial lidocaine in peri- and post-procedural pain and hospitalization. ( Giojelli, A; Romano, M; Salvatore, M; Tamburrini, O, 2003) |
| "As a predictor of hepatic failure after TACE, the monoethylglycinexylidide test is better than conventional liver function tests and clinical parameters." | 7.71 | Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. ( Chang, FY; Chiang, JH; Huang, YS; Lee, SD; Wu, JC, 2002) |
| "2) l/m2] and the effective half-life [t1/2eff, 5." | 5.30 | Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ( Aita, P; Boiocchi, M; Cannizzaro, R; Colussi, AM; Corona, G; Robieux, I; Sorio, R; Toffoli, G; Tumolo, S, 1999) |
| "The pharmacokinetics and clinical activity of epirubicin were investigated in 16 patients with hepatocellular carcinoma (HCC) who received epirubicin at 75 mg/m2; the drug was given intravenously to 7 patients and via the hepatic artery to 9 patients (7 of whom also underwent embolisation)." | 5.07 | Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity. ( Dobbs, NA; Johnson, PJ; Metivier, EM; Rizzi, P; Twelves, CJ; Warwick, JD; Williams, R, 1994) |
| "Lidocaine plays an anticancer role in hepatocellular carcinoma." | 4.02 | Lidocaine Inhibits Hepatocellular Carcinoma Development by Modulating circ_ITCH/miR-421/CPEB3 Axis. ( Chen, F; Li, J; Liu, G; Ma, N; Mao, N; Zhao, L, 2021) |
| "Lidocaine displays antitumor activity by inducing apoptosis and suppressing tumor growth in human hepatocellular carcinoma (HepG2) cells in vitro." | 3.88 | Effects of Lidocaine-Mediated CPEB3 Upregulation in Human Hepatocellular Carcinoma Cell Proliferation In Vitro. ( Chen, B; Li, W; Liu, H; Shen, X; Wang, Y, 2018) |
| " However, the function and underlying mechanisms of lidocaine in hepatocellular carcinoma both in vitro and in vivo have been poorly studied." | 3.85 | Lidocaine Induces Apoptosis and Suppresses Tumor Growth in Human Hepatocellular Carcinoma Cells In Vitro and in a Xenograft Model In Vivo. ( Chen, DT; Chen, YH; Li, Q; Pan, JH; Xing, W; Xue, RF; Yan, Y; Yuan, YF; Zeng, WA, 2017) |
| "To assess the efficacy of intraarterial lidocaine on peri- and post-procedural pain and on length of hospital stay in hepatocellular carcinoma (HCC) patients undergoing chemoembolization." | 3.72 | Chemoembolization for hepatocellular carcinoma: effect of intraarterial lidocaine in peri- and post-procedural pain and hospitalization. ( Giojelli, A; Romano, M; Salvatore, M; Tamburrini, O, 2003) |
| "As a predictor of hepatic failure after TACE, the monoethylglycinexylidide test is better than conventional liver function tests and clinical parameters." | 3.71 | Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. ( Chang, FY; Chiang, JH; Huang, YS; Lee, SD; Wu, JC, 2002) |
| "The lidocaine (MEGX [monoethylglycinexylidide]) test, which was performed in 200 patients with different liver diseases and in 23 organ donors, was compared with common laboratory tests." | 3.70 | The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery. ( Callivà, R; Cavallari, A; Cescon, M; Ercolani, G; Grazi, GL; Mazziotti, A; Pierangeli, F, 2000) |
| "Sixteen patients with hepatocellular carcinoma in cirrhotic livers were enrolled in this study." | 1.33 | Assessment of hepatic reserve for indication of hepatic resection: how I do it. ( Chen, MF; Lee, WC, 2005) |
| "Hepatocellular carcinoma is likely to accompany liver cirrhosis in which the portal pressure increases with portasystemic shunt." | 1.32 | Experimental study of the evaluation of liver function on the opposite side during portacaval anastomosis and ligation of the left portal branch. ( Fukuda, Y; Matsuyama, K; Miyake, H; Tashiro, S; Yogita, S, 2004) |
| "2) l/m2] and the effective half-life [t1/2eff, 5." | 1.30 | Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ( Aita, P; Boiocchi, M; Cannizzaro, R; Colussi, AM; Corona, G; Robieux, I; Sorio, R; Toffoli, G; Tumolo, S, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.09) | 18.7374 |
| 1990's | 5 (22.73) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 5 (22.73) | 24.3611 |
| 2020's | 4 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 2 |
| Jia, J | 1 |
| Jin, W | 1 |
| Cao, J | 1 |
| Fu, T | 1 |
| Ma, D | 1 |
| Wu, Z | 1 |
| Guo, W | 1 |
| Chen, S | 1 |
| Zhuang, W | 1 |
| Bucatariu, SM | 1 |
| Constantin, M | 1 |
| Varganici, CD | 1 |
| Rusu, D | 1 |
| Nicolescu, A | 1 |
| Prisacaru, I | 1 |
| Carnuta, M | 1 |
| Anghelache, M | 1 |
| Calin, M | 1 |
| Ascenzi, P | 1 |
| Fundueanu, G | 1 |
| Zhao, L | 1 |
| Ma, N | 1 |
| Liu, G | 1 |
| Mao, N | 1 |
| Chen, F | 1 |
| Li, J | 1 |
| Jurj, A | 1 |
| Tomuleasa, C | 1 |
| Tat, TT | 1 |
| Berindan-Neagoe, I | 1 |
| Vesa, SV | 1 |
| Ionescu, DC | 1 |
| Le Gac, G | 1 |
| Angenard, G | 1 |
| Clément, B | 1 |
| Laviolle, B | 1 |
| Coulouarn, C | 1 |
| Beloeil, H | 1 |
| Liu, H | 1 |
| Wang, Y | 1 |
| Chen, B | 1 |
| Shen, X | 1 |
| Li, W | 1 |
| Chang, BX | 1 |
| You, SL | 1 |
| Liu, HL | 1 |
| Mao, PY | 1 |
| Xin, SJ | 1 |
| Xing, W | 1 |
| Chen, DT | 1 |
| Pan, JH | 1 |
| Chen, YH | 1 |
| Yan, Y | 1 |
| Li, Q | 1 |
| Xue, RF | 1 |
| Yuan, YF | 1 |
| Zeng, WA | 1 |
| Romano, M | 1 |
| Giojelli, A | 1 |
| Tamburrini, O | 1 |
| Salvatore, M | 1 |
| Matsuyama, K | 1 |
| Fukuda, Y | 1 |
| Miyake, H | 1 |
| Yogita, S | 1 |
| Tashiro, S | 1 |
| Lee, WC | 1 |
| Chen, MF | 1 |
| Dobbs, NA | 1 |
| Twelves, CJ | 1 |
| Rizzi, P | 1 |
| Warwick, JD | 1 |
| Metivier, EM | 1 |
| Williams, R | 1 |
| Johnson, PJ | 1 |
| Shamberger, RC | 1 |
| Leichtner, AM | 1 |
| Jonas, MM | 1 |
| LaQuaglia, MP | 1 |
| Nakamura, H | 1 |
| Oi, H | 1 |
| Aita, P | 1 |
| Robieux, I | 1 |
| Sorio, R | 1 |
| Tumolo, S | 1 |
| Corona, G | 1 |
| Cannizzaro, R | 1 |
| Colussi, AM | 1 |
| Boiocchi, M | 1 |
| Toffoli, G | 1 |
| Ercolani, G | 1 |
| Grazi, GL | 1 |
| Callivà, R | 1 |
| Pierangeli, F | 1 |
| Cescon, M | 1 |
| Cavallari, A | 1 |
| Mazziotti, A | 1 |
| Ohmoto, K | 1 |
| Yamamoto, S | 1 |
| Huang, YS | 1 |
| Chiang, JH | 1 |
| Wu, JC | 1 |
| Chang, FY | 1 |
| Lee, SD | 1 |
| Molgaard, CP | 1 |
| Teitelbaum, GP | 1 |
| Pentecost, MJ | 1 |
| Finck, EJ | 1 |
| Davis, SH | 1 |
| Dziubinski, JE | 1 |
| Daniels, JR | 1 |
| Jackson, SH | 2 |
| Epstein, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study[NCT02293447] | Phase 4 | 60 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for lidocaine and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity.
Topics: Adult; Aged; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Chromatography, High Pressure L | 1994 |
21 other studies available for lidocaine and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Lidocaine inhibits the proliferation and invasion of hepatocellular carcinoma by downregulating USP14 induced PI3K/Akt pathway.
Topics: Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Down-Regulation; Humans; Lidocaine; Li | 2020 |
Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analgesics; Anesthetics, Local; Antineoplastic Combined | 2021 |
A new sponge-type hydrogel based on hyaluronic acid and poly(methylvinylether-alt-maleic acid) as a 3D platform for tumor cell growth.
Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Diphenhydramine; Hep G2 Cells; Humans; Hy | 2020 |
Lidocaine Inhibits Hepatocellular Carcinoma Development by Modulating circ_ITCH/miR-421/CPEB3 Axis.
Topics: Anesthetics, Local; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Lidocaine; Liver N | 2021 |
Antiproliferative and Apoptotic Effects of Lidocaine on Human Hepatocarcinoma Cells. A preliminary study.
Topics: Anesthetics, Local; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relation | 2017 |
Local Anesthetics Inhibit the Growth of Human Hepatocellular Carcinoma Cells.
Topics: Amides; Anesthetics, Local; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle Proteins; Ce | 2017 |
Effects of Lidocaine-Mediated CPEB3 Upregulation in Human Hepatocellular Carcinoma Cell Proliferation In Vitro.
Topics: Carcinoma, Hepatocellular; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gene Knockdow | 2018 |
Establishment of cytochrome P450 3A4 and glutathione S-transferase A1-transfected human hepatoma cell line and functional analysis.
Topics: Anesthetics, Local; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cytochrome P-450 CYP | 2014 |
Lidocaine Induces Apoptosis and Suppresses Tumor Growth in Human Hepatocellular Carcinoma Cells In Vitro and in a Xenograft Model In Vivo.
Topics: Anesthetics, Local; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferat | 2017 |
Chemoembolization for hepatocellular carcinoma: effect of intraarterial lidocaine in peri- and post-procedural pain and hospitalization.
Topics: Abdominal Pain; Aged; Anesthetics, Local; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2003 |
Experimental study of the evaluation of liver function on the opposite side during portacaval anastomosis and ligation of the left portal branch.
Topics: Animals; Carcinoma, Hepatocellular; Dogs; Humans; Indocyanine Green; Lidocaine; Ligation; Liver Circ | 2004 |
Assessment of hepatic reserve for indication of hepatic resection: how I do it.
Topics: Carcinoma, Hepatocellular; Female; Hepatectomy; Humans; Lidocaine; Liver Cirrhosis; Liver Failure; L | 2005 |
Long-term hepatic regeneration and function in infants and children following liver resection.
Topics: Adolescent; Adult; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Child; Child, Preschool; Combi | 1996 |
Chemoembolization for small hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Epirubicin; Humans; Infusions, Intra-Arte | 1997 |
Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Aspartate Aminotra | 1999 |
The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Carcinoma, Hepatocellular | 2000 |
Percutaneous microwave coagulation therapy for superficial hepatocellular carcinoma using intraperitoneal infusion of local anesthetic.
Topics: Aged; Anesthetics, Local; Carcinoma, Hepatocellular; Electrocoagulation; Female; Humans; Injections, | 2001 |
Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Lidocaine; Liver Fa | 2002 |
Intraarterial administration of lidocaine for analgesia in hepatic chemoembolization.
Topics: Adult; Aged; Analgesia; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therape | 1990 |
The metabolic effects of nonvolatile anesthetics on mammalian hepatoma cells in vitro. II. Inhibition of macromolecular precursor incorporation.
Topics: Amobarbital; Animals; Carcinoma, Hepatocellular; Culture Techniques; DNA, Neoplasm; Leucine; Lidocai | 1971 |
The metabolic effects of nonvolatile anesthetics on mammalian hepatoma cells in vitro. I. Inhibition of cell replication.
Topics: Amobarbital; Anesthetics, Local; Animals; Barbiturates; Carcinoma, Hepatocellular; Cell Count; Cell | 1971 |